MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

September 1, 2022

AGENDA ITEM

Thursday, September 1, 2022

PRESIDER/PRESENTER(s)

10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair)
		Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:15	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Update on SARS-CoV-2 Variants and the Epidemiology of COVID-19	Dr. Heather Scobie (CDC/NCIRD)
	Immunology of SARS-CoV-2 variants	Dr. Natalie Thornburg (CDC/NCIRD)
	Updates to COVID-19 vaccine effectiveness in the United States	Dr. Ruth Link-Gelles (CDC/NCIRD)
	COVID-19 vaccine safety updates	Dr. Tom Shimabukuro (CDC/NCEZID)
12:00	Break	
12:15	Public Comment	
12:45	Break	
1:00	Moderna COVID-19 Bivalent vaccine (Original and Omicron BA.4/BA.5)	Dr. Jacqueline Miller (Moderna)
2:30	Pfizer/BioNTech COVID-19 Omicron-modified Bivalent vaccine candidate Break	Dr. Kena Swanson (Pfizer)
2:30 2:45	Evidence to recommendation Framework: Bivalent COVID-19 vaccine booster doses	Dr. Sara Oliver (CDC/NCIRD)
	Clinical Considerations update	Dr. Elisha Hall (CDC/NCIRD)
4:30	VOTE	
	Pfizer-BioNTech COVID-19 vaccine, Bivalent in individuals ages 12 years and older	Dr. Sara Oliver (CDC/NCIRD)
	Moderna COVID-19 vaccine, Bivalent in individuals ages 18 years and older	
5:00	Adjourn	
Acronyms		
CDC	Centers for Disease Control and Prevention	
CMS	Centers for Medicare and Medicaid Services	
COVID-19	Coronavirus disease 2019	
EtR FDA	Evidence to Recommendations Framework Food and Drug Administration	
GRADE	Grading of Recommendations Assessment, Development and Evaluation	
HRSA	Health Resources and Services Administration	
IHS	Indian Health Service	
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/DDID]	
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/DDID]	
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/DDID]	
	National Institute of Allergy and Infectious Diseases	
OIDP SARS-CoV-2	Office of Infectious Disease and HIV/AIDS Policy Severe Acute Respiratory Syndrome Coronavirus 2	
WG	Work Group	
WHO	World Health Organization	
VaST	COVID-19 Vaccine Safety Technical (VaST) Work Group	
VE	Vaccine Effectiveness	